OTCPK:VTRL.Y

Stock Analysis Report

Executive Summary

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction.

Rewards

Earnings are forecast to grow 13.35% per year

Earnings have grown 22.5% per year over the past 5 years

Risk Analysis

No risks detected for VTRL.Y from our risk checks.


Snowflake Analysis

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Vitrolife's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VTRL.Y has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

VTRL.Y

0.5%

US Biotechs

0.06%

US Market


1 Year Return

n/a

VTRL.Y

14.1%

US Biotechs

19.3%

US Market

Return vs Industry: Insufficient data to determine how VTRL.Y performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how VTRL.Y performed against the US Market.


Shareholder returns

VTRL.YIndustryMarket
7 Day0%0.5%0.06%
30 Day0%2.8%1.7%
90 Day0%8.2%9.0%
1 Yearn/a15.0%14.1%21.8%19.3%
3 Yearn/a24.2%20.9%49.5%39.9%
5 Yearn/a3.1%-1.7%73.1%54.1%

Price Volatility Vs. Market

How volatile is Vitrolife's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Vitrolife undervalued compared to its fair value and its price relative to the market?

61.27x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: VTRL.Y ($16.35) is trading above our estimate of fair value ($6.92)

Significantly Below Fair Value: VTRL.Y is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: VTRL.Y is poor value based on its PE Ratio (61.3x) compared to the Biotechs industry average (20.1x).

PE vs Market: VTRL.Y is poor value based on its PE Ratio (61.3x) compared to the US market (18.9x).


Price to Earnings Growth Ratio

PEG Ratio: VTRL.Y is poor value based on its PEG Ratio (4.6x)


Price to Book Ratio

PB vs Industry: VTRL.Y is overvalued based on its PB Ratio (13.2x) compared to the US Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Vitrolife forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

13.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VTRL.Y's forecast earnings growth (13.4% per year) is above the savings rate (1.7%).

Earnings vs Market: VTRL.Y's earnings (13.4% per year) are forecast to grow slower than the US market (14.3% per year).

High Growth Earnings: VTRL.Y's earnings are forecast to grow, but not significantly.

Revenue vs Market: VTRL.Y's revenue (11.3% per year) is forecast to grow faster than the US market (7.5% per year).

High Growth Revenue: VTRL.Y's revenue (11.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VTRL.Y's Return on Equity is forecast to be high in 3 years time (22.1%)


Next Steps

Past Performance

How has Vitrolife performed over the past 5 years?

22.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VTRL.Y has high quality earnings.

Growing Profit Margin: VTRL.Y's current net profit margins (26.7%) are lower than last year (26.7%).


Past Earnings Growth Analysis

Earnings Trend: VTRL.Y's earnings have grown significantly by 22.5% per year over the past 5 years.

Accelerating Growth: VTRL.Y's earnings growth over the past year (26%) exceeds its 5-year average (22.5% per year).

Earnings vs Industry: VTRL.Y earnings growth over the past year (26%) underperformed the Biotechs industry 103.3%.


Return on Equity

High ROE: VTRL.Y's Return on Equity (21.5%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Vitrolife's financial position?


Financial Position Analysis

Short Term Liabilities: VTRL.Y's short term assets (SEK1.1B) exceed its short term liabilities (SEK223.1M).

Long Term Liabilities: VTRL.Y's short term assets (SEK1.1B) exceed its long term liabilities (SEK141.6M).


Debt to Equity History and Analysis

Debt Level: VTRL.Y's debt to equity ratio (4.5%) is considered satisfactory.

Reducing Debt: VTRL.Y's debt to equity ratio has reduced from 7.2% to 4.5% over the past 5 years.

Debt Coverage: VTRL.Y's debt is well covered by operating cash flow (511.2%).

Interest Coverage: VTRL.Y earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: VTRL.Y has a low level of unsold assets or inventory.

Debt Coverage by Assets: VTRL.Y's debt is covered by short term assets (assets are 13.6x debt).


Next Steps

Dividend

What is Vitrolife's current dividend yield, its reliability and sustainability?

0.41%

Current Dividend Yield


Dividend Yield vs Market

company0.4%marketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0.7%

Current dividend yield vs market & industry

Notable Dividend: VTRL.Y's dividend (0.41%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.4%).

High Dividend: VTRL.Y's dividend (0.41%) is low compared to the top 25% of dividend payers in the US market (3.66%).


Stability and Growth of Payments

Stable Dividend: VTRL.Y is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: VTRL.Y is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: VTRL.Y is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VTRL.Y's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Thomas Axelsson (60yo)

7.8yrs

Tenure

0

Mr. Thomas Axelsson, M.Sc. employed at Vitrolife AB (publ) in 2011 and has been its Chief Executive Officer of since April 18, 2012. Mr. Axelsson served as an Acting Chief Executive Officer of Vitrolife fr ...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD3.86M).

Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Axelsson
Chief Executive Officer7.8yrsno data0.093% SEK2.2m
Mikael Engblom
CFO & Investor Relations0yrsno data0.019% SEK459.2k
Steffen Nielsen
Chief Operating Officer2.3yrsno data0.0080% SEK191.2k
Claus Bisgaard
Vice President of Technology0yrsno datano data
Mark Larman
Chief Scientific Officer2.4yrsno data0.0021% SEK51.3k
Rickard Ericsson
Chief Sales & Marketing Officer2.3yrsno data0.0069% SEK165.8k
Martin Morén
Director of Human Resources11.9yrsno datano data
Fredrik Mattsson
Senior Vice President of New Business & Strategic Development1.3yrskr100.00k0.043% SEK1.0m
Maria Forss
Business Unit Director of Media2.3yrsno data0.011% SEK259.3k
Jan Nilsson
Head Auditor 0yrsno datano data

2.3yrs

Average Tenure

47yo

Average Age

Experienced Management: VTRL.Y's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Henrik Blomquist
Independent Director0.7yrsno datano data
Jón Sigurdsson
Chairman0.7yrsno data0.028% SEK671.9k
Lars Holmqvist
Independent Director2yrsno datano data
Pia Marions
Independent Director6.8yrsno data0.0046% SEK110.6k

1.3yrs

Average Tenure

58yo

Average Age

Experienced Board: VTRL.Y's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Vitrolife AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vitrolife AB (publ)
  • Ticker: VTRL.Y
  • Exchange: OTCPK
  • Founded: 1981
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr22.709b
  • Listing Market Cap: kr2.399b
  • Shares outstanding: 108.55m
  • Website: https://www.vitrolife.com

Number of Employees


Location

  • Vitrolife AB (publ)
  • Gustaf Werners gata 2
  • Västra Frölunda
  • Gothenburg
  • 421 32
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VITROM (OMX Nordic Exchange Stockholm)YesCommon SharesSESEKJun 2001
VTFNDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2001
0YAYLSE (London Stock Exchange)YesCommon SharesGBSEKJun 2001
VITRSBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBSEKJun 2001
VTRL.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDMay 2016

Biography

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It offers oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; cryopreservation; and preimplantation genetic testing products. The company also provides EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors; and pH online. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1981 and is headquartered in Gothenburg, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/01/14 02:27
End of Day Share Price2019/10/16 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.